S-2E

Cat. No.:	HY-139134
CAS No.:	155730-92-0
Molecular Formula:	$C_{22}H_{25}NO_4$
Molecular Weight:	367.44
Target:	HMG-CoA Reductase (HMGCR); Acetyl-CoA Carboxylase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research[1][2].
In Vivo	In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at K_i=18.11 μM and K_i=69.2 μM, respectively[1]. S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Koichi Ohmori, et al. Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol. 2003 Jun 13;471(1):69-76.

[2]. K Ohmori, et al. Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism. 2004 May;53(5):680-5.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA